Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Exacctnt who wrote (18999)	4/14/1998 8:42:00 AM
From: Henry Niman	Read Replies (2) of 32384

Bob, Those moaners and groaners should look at today's NY Times. The science section has an article on Tamoxifen (who should take it for prevention of breast cancer). Although the article indicates that participants in the prevention study will be give the opportunity to "enter another study in which patients would be given either tamoxifen or a similar drug, with no one getting placebos." there is no indication that the "simialr drug" is LLY's Evista, aka Raloxifene. The artcle does close with brief discussion of SERMs and this tantalizing sentence for LGND lovers: "Dr. Ford said that researchers were also trying to find out whether adding other drugs to tamoxifen might protect the uterus". As most shareholders who post here know, Targretin has been shown to protect the uterus in rats given tamoxifen, and Panretin is in at least two combination trials with tamoxifen for women with breast cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next